Published in final edited form as:

Biochem Pharmacol. 2009 March 1; 77(5): 761–769. doi:10.1016/j.bcp.2008.10.006.

RLIP76: A novel glutathione-conjugate and multi-drug transporter

Sharad S. Singhal^{*}, Sushma Yadav, Cherice Roth, and Jyotsana Singhal

Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, TX 76107, United States

Abstract

RLIP76, a stress-responsive, multi-functional protein with multi-specific transport activity towards glutathione-conjugates (GS-E) and chemotherapeutic agents, is frequently over-expressed in malignant cells. Our recent studies suggest that it plays a prominent anti-apoptotic role selectively in cancer cells. We have previously shown that RLIP76 accounts for up to 80% of the transport of GS-E and blocking the RLIP76-mediated transport of GS-E in cells results in the accumulation of pro-apoptotic endogenous electrophiles and on-set of apoptosis. Here we demonstrate that when RLIP76 mediate transport of GS-E is abrogated either by anti-RLIP76 IgG or accumulation of 4-hydroxynonenal (4-HNE) and its GSH-conjugate (GS-HNE) occurs and a massive apoptosis is observed in cells, indicate that the inhibition of RLIP76 transport activity at the cell surface is sufficient for observed anti-tumor activity. RLIP76 is linked with certain cellular functions including membrane plasticity and movement (as a primary 'effector' in the Ral pathway, perhaps functioning as a GTPase activating protein, or GAP), and as a component of clathrin-coated pit-mediated receptor-ligand endocytosis—a process that mediates movement of membrane vesicles.

Keywords

RLIP76; Cancer; Drug-resistance; Glutathione-conjugate transport; Xenografts

1. Introduction

RLIP76 (Ral-interacting protein) is a stress-responsive, multi-specific membrane transport protein, which accounts for the majority of glutathione-electrophile conjugates (GS-E) transport in mammalian cells including human, is a critical component of stress-response in cultured cells and provides protection from stressors including heat, oxidant chemicals, chemotherapeutic agents, UV irradiation and X-irradiation [1-8]. Human RLIP76 (655 aa), rat RalBP1 (647 aa) and mouse RIP1 (648 aa), are highly homologous, having 88% identity in nucleotides and 92% amino acid similarity, and have been shown to be functionally identical [9]. All three contain a Ral-binding domain (aa ~390-445) that binds Ral-GTP through the effector domain of Ral. Residue 49N in the effector domain of Ral is critically important for binding [10]. A Rho/Rac GAP homology domain (aa ~210-357), also present in all three, and is homologous (35% identity) with the Rho-GAP domain of breakpoint cluster region protein (BCR) which exhibits Rho-GAP activity towards Rac and cdc42 [11]. RLIP76, RalBP1 and RIP1 display definite but relatively weak GTPase activating (GAP) activity towards Rac1 and cdc42, but not towards Ral [12]. Other common characteristics of RLIP76, RalBP1 and RIP1 include their sub-cellular distribution largely in the membrane and particulate fraction. Taken together, studies of structure, function and protein binding of RLIP76, RalBP1 and RIP1

^{*}Corresponding author at: Department of Molecular Biology and Immunology, 3500 Camp Bowie Blvd., University of North Texas Health Science Center, Fort Worth, TX 76107-2699, United States. Tel.: +1 817 735 0459; fax: +1 817 735 2118. E-mail address: ssinghal@hsc.unt.edu (S.S. Singhal).

indicate that these are closely similar orthologues with likely to serve very similar if not identical functions across these species. In this article, to avoid confusion we uniformly refer to this protein and to its mouse (RIP1) [13] or rat counterpart (RalBP1) [10] collectively as RLIP76 [2,14]. The Pgp and MRP families of proteins have been extensively reviewed [15-19] and hence they are not covered in this article. In the present article, we review the molecular identity, functional and structural characteristics of RLIP76 and discuss their physiological role in the multi-drug-resistance of cancer cells.

2. RLIP76 is a non-ABC multi-functional protein

RLIP76 is a multi-functional modular protein found ubiquitously from drosophila to humans [10,13,14,20,21]. It is encoded in humans on chromosome 18p11.3 by a gene with 11 exons and 9 introns [22]. RLIP76 is a 76 kDa protein product of this gene, but splice-variants including a 67 kDa peptide and longer 80 or 102 kDa peptide, cytocentrin have been identified [9,23]. It was cloned originally as a Ral-binding GTPase-activating protein (GAP), and predicted to be a Ral-effector, through a yeast two-hybrid screen [14,24,25]. We cloned RLIP76 independently, in the search for GS-E and chemotherapy drug transporters, from a human bone-marrow cDNA library using polyclonal antibodies raised against purified human erythrocyte putative membrane transporter, DNPSG-ATPase [2,26,27]. The identity of RLIP76 with DNPSG-ATPase was demonstrated by showing that both the human and recombinant protein could be purified by the same GS-E affinity chromatography method [1,2,26]. Tissue-purified and recombinant RLIP76 have been demonstrated to function in isolated *in vitro* systems as well as *in vivo* studies to be an ATP-dependent transporter of GS-E as well as of the amphiphilic anti-cancer drugs such as doxorubicin (DOX), colchicine, vincristine, vinblastine and vinorelbine [1-6,26-28]. Studies demonstrating the marked enhancement of vinorelbine efficacy in lung and colon cancer xenografts by concomitant depletion or inhibition of RLIP76 have confirmed the *in vivo* relevance of these observations [8].

RLIP76 is a modular protein containing a GAP domain [14], protein-protein interaction domains [29], antennapedia homeodomain homologous sequences, leucine-zipper domain, and consensus sequences for protein and tyrosine-kinase phosphorylation and N-myristoylation [30-33]. RLIP76, a novel R-Ras effector, links R-Ras to adhesion-induced Rac activation through a GTPase cascade that mediates cell spreading and migration [34]. GAP activity of RLIP76 has been demonstrated towards Rho/Rac G-proteins that are known to regulate cell membrane plasticity, endocytosis, cell motility, and xenobiotic and stress-responses [14, 35-37]. RLIP76 has been shown to bind to a number of important signaling proteins including Ral, clathrin adaptor AP2 [20], Hsf-1, HSP90 [38], partner of RalBP1 (POB1) [39-41], and CDK1 (cdc-2) [42]. These studies with human RLIP76 as well as its mouse (RIP1) and rat (RalBP1) homologs have linked it with a bewildering array of functions including clathrin-coated-pit-mediated receptor-ligand endocytosis of signals including those from insulin and TGF- β receptors, mitosis signaling through CDK1, mitotic spindle movement, and neurotransmitter exocytosis in exocyst complex [9,25,42-45]. The mechanisms through which RLIP76 participates in these functions have been unclear.

Augmenting cellular RLIP76 through stable transfection or through liposomal delivery confers resistance to DOX [2,5]. The GS-E transport function has been shown in several models of cultured cells to be a mechanism for providing protection from diverse stressors including heat, oxidants, UVA, and X-rays, all of which are known to increase cellular GS-E formed from reactive electrophilic intermediates of membrane lipid-oxidation [1,30-32,36,37,46-48]. Most remarkably, acute inhibition of RLIP76 transport activity using specific antibody that recognizes a cell-surface epitope of RLIP76, causes apoptosis [30,48]. Our findings showing that RLIP76 is an ATP-dependent transporter of GS-E and certain xenobiotics, suggest a novel paradigm for signaling of apoptosis, mitosis, cell motility, chemotaxis, endocytosis,

exocytosis, stress-defenses and drug-resistance, in which RLIP76 is the chief-regulator of levels of cellular GS-E which are critical chemical signals in common for all of these processes.

This hypothesis predicts that RLIP76 should be a primary determinant of cellular resistance to the stress in the form of chemicals, heat or irradiation. To test this hypothesis, we generated C57B mice which carry heterozygous (+/-) or homozygous (-/-) deletion of the RLIP76 gene. These mice were commissioned from Lexicon Genetics and were created using Cre-Lox technology [49], which can selectively suppress genes. From RLIP76^{+/-} animals, obtained from Lexicon Genetics, we established colonies of RLIP76^{+/+}, RLIP76^{+/-} and RLIP76^{-/-} mice by segregation and mating of animals based on genotyping by PCR on tail tissue as described [6]. Western-blot analysis of mouse tissues using anti-RLIP76 antibodies confirmed decreased RLIP76 levels in the RLIP76^{+/-} mouse, and its absence in tissues from the RLIP76^{-/-} mouse as demonstrated by us [6,50].

3. Structural motifs of RLIP76

Primary structure of RLIP76 can be divided into four regions. N-terminal domain (aa 1-209), is rich in antennapedia homeodomain homologous peptides. These peptides are known to be capable of transporting of wide range of substrates across membranes. Two central domains include, one carrying a Rac/cdc42 GAP (through aa 210-357) activity, while the other binds to activated Ral (aa 391-499). A C-terminal coiled-coil domain (aa 500-647) has subsequently been shown to interact with Rps1/POB1, CDK1 and Hsf-1. These structural features link RLIP76 to a confounding array of physiological functions including clathrin-coated-pit-mediated receptor-ligand endocytosis of epidermal growth factor receptor (EGFR), insulin receptor (IR) and transforming growth factor β (TGF- β) as well as mitosis signaling [9, 30-33,38-43].

From the sequence alignment studies of RLIP76 using Blast search engine, the following sites were identified as potential candidate motifs in the primary structure of RLIP76. N-terminal and C-terminal ATP-binding domains at amino acids 69-74 and 418-425, respectively; several N-myristoylation sites were located at amino acids 21-26, 40-45 and 191-196; N-glycosylation site at amino acid 341-344; cyclic adenosine-monophosphate (cAMP) binding site at amino acid 113-116; cAMP-dependent protein kinase phosphorylation sites at amino acids 308-315; leucine zipper pattern at amino acids 547-578; several protein kinase C and casein kinase II phosphorylation sites and trypsin and chymotrypsin cut sites. Two ATP binding sites on N and C-terminal domains [46], PKC α phosphorylation sites [30,51,52], several regions that have high sequence homology with the vector-peptides and membrane-associated proteins, that play an important role in transport and membrane anchorage and a cell-surface domain have being experimentally confirmed through site-directed mutagenesis studies using substitution and deletion mutant analyses [3].

4. Role of RLIP76 in endocytosis

RLIP76 is a novel link between GSH-linked oxidant defense, phase I and II biotransformation, stress signaling, receptor-ligand pair endocytosis and Ral and Rac-1 signaling pathways [14, 30-37]. The role of RLIP76 in G-protein signaling includes mainly its functions as an effector protein bridging Ras-Ral pathways. It is regulated by Ral and displays GAP-activity (inhibitory) towards Rho proteins most importantly cdc42, a pro-apoptotic G-protein that exerts an inhibitory effect on Ras. RLIP76 is also an integral component of complexes containing Ral, clathrin-adaptor protein AP2, POB1 and Epsin which are involved in the clathrin-coated-pit-mediated receptor-ligand endocytosis, a mechanism for internalizing receptor-ligand pairs that terminate signaling [42,43].

RLIP76 and POB1 are downstream molecules of small GTP binding protein Ral. The presence of EH-domain in both RLIP76 as well as POB1 suggests them to play a role in clathrin-dependent endocytosis [35]. This hypothesis has been seen to be true by both proteins being involved in receptor-mediated endocytosis together with Epsin and EPS15. In the course of endocytosis, RLIP76, POB1, Epsin and EPS15 form a complex with alpha-adaptin of AP2. During the mitotic phase of the cell, complex formation is reduced by phosphorylation of Epsin by p34cdc2. Phosphorylation inhibits the complex formation by inhibiting the binding of POB1 to EH domain [9,53]. C-terminal domain of RLIP76 is involved in EGF-receptor endocytosis via an interaction with POB1 [54].

In the event of endocytosis, Ras activation activates Ral-GEFs which in turn activate Ral. Activated Ral associates with Ral effector RLIP76 and recruited it to the membrane [20]. RLIP76 sorts out the plasma membrane clathrin adaptor AP2 complex from the trans-golgi network clathrin adaptor AP1 complex. AP2 works exclusively at plasma membrane while AP1 works at golgi network. RLIP76 binds specifically with mu2 subunit of the AP2. Requirement of GTPases at various stages of a coated pit cycle has been demonstrated in endocytosis assays in semi-intact cells [20,55]. Role of dynamin clearly established the requirement of GTP binding proteins at the stage of membrane docking of AP2 and the role during formation of coated pits remains to be elucidated. Equilibrium between GTP and GDP-bound Ral could regulate the association of AP2 with the membrane. Trapping Ral in its GTP bound form stabilizes the mu/RLIP76 binding with membranes and thus disrupts the dynamic cycles of AP membranes interactions, i.e. association and dissociation that are required for coated pits assembly and disassembly [20]. Therefore Ral in its GTP bound form inhibits the endocytosis.

During mitotic phase, POB1, RLIP76 and Epsin are phosphorylated by p34cdc2. Phosphorylation of RLIP76 does not effect binding with POB1 or vice versa. Receptor-mediated endocytosis is completely arrested during mitosis by disassembly of its complex with POB1 and alpha adaptin. Phosphorylated RLIP76 may associate with centrosome. It is being hypothesized that during mitotic phase RLIP76/POB1 may interact with different proteins and function in assembly of mitotic apparatus as they are involved in assembly of receptor and endocytotic proteins during the interphase [29,35,42,53].

5. RLIP76 in stress resistance

The stress inducible nature of RLIP76 has been demonstrated in several different malignant cell lines, with various types of stresses, such as chemical (e.g. doxorubicin, naphthalene), oxidative (ROS), radiation (UV, X-ray) or heat [6,30,36,37,50]. It has been experimentally established that RLIP76 is required for PKC α -mediated cell proliferation pathways [51,56] as well as for protection through heat-shock proteins (HSPs) [38,41].

Depletion of PKC α causes ~30% decrease in rate of proliferation of mouse embryonic fibroblast cells (MEFs). This decrease is absent in RLIP76 gene knockout (RLIP76^{-/-}) MEFs. PKC α stimulate DOX-resistance by increased efflux, in RLIP76^{+/+} MEFs while RLIP76^{-/-} MEFs lack this phenotype completely. These results lead to the definitive conclusion that RLIP76 is downstream of PKC α and is required for PKC α -mediated signal proliferation [52, 56].

During normal physiological conditions, expression of HSPs is regulated by sequestering the transcription factor Hsf-1 by an interaction with RLIP76 [38,41]. During heat shock, under the activation of Ral, Hsf-1:RLIP76 complex dissociates and hence the expression of heat-shock proteins are transcriptionally activated by Hsf-1. However despite the induction of HSPs, RLIP76^{-/-} mice are markedly sensitive to radiation, which could be overcome by intra-

peritoneal administration of RLIP76 in proteoliposomes [6,50]. That is, HSPs (known to be radiation protective proteins) also cannot function in the absence of RLIP76.

6. RLIP76 is necessary for PKC α -mediated DOX-resistance

Non-small cell lung cancer (NSCLC) cells are inherently more resistant to chemotherapeutic agent DOX as compared to small cell lung cancer (SCLC) [23,47,51,52,56]. Since RLIP76 is a key transporter responsible for drug-accumulation defect consisting of several PKC α -phosphorylation sites, we investigated the role of PKC α -activity on transport properties of RLIP76. The enhanced transport activity of RLIP76 by PKC α -mediated phosphorylation, lead us to the hypothesis, differential PKC α -mediated phosphorylation as a cause for the variations of drug-resistance observed in NSCLC and SCLC. Higher expression of PKC α in NSCLC as compared to SCLC as well as, the decrease of IC₅₀ value of NSCLC for DOX, to the level of SCLC, by depletion of PKC α confirmed our hypothesis to be true. Although RLIP76^{-/-} MEFs were significantly more sensitive to DOX as compared to RLIP76^{+/+} MEFs (IC₅₀ 25 vs 125 nM), depletion of PKC α only affected the DOX-sensitivity of RLIP76^{+/+} MEFs. These experimental data confirmed that RLIP76 is necessary for the PKC α -mediated drug-resistance signaling [51,52,56]. Recent studies by others have identified a large number of differentially phosphorylated forms of RLIP76 [57].

The studies using recombinant-RLIP76 proteoliposomes in the presence of PKC α indicated enhanced transport of both endobiotics (LTC₄) as well as xenobiotics (DNP-SG) [4]. In order to answer the question whether PKC α -mediated phosphorylation of RLIP76 as a cause for differential drug-resistance observed in NSCLC and SCLC, we determined the expression of PKC α in several NSCLC and SCLC cell lines. Western-blot analysis using antibodies against PKC α , with equal amount of crude protein from either cell lines indicated a higher expression of PKC α in all NSCLC cell lines as compared to SCLC cell lines [51,52]. Depletion of PKC α by siRNA, in several NSCLC and SCLC cell lines, showed a decrease in the drug-resistance (IC₅₀ for DOX) of NSCLC cell lines to the level observed with SCLC cell lines. Same phenomenon was observed in DOX-transport studies using proteoliposomes reconstituted with purified RLIP76 from PKC α depleted NSCLC and SCLC. These results directly indicate that PKC α play a major role towards differential DOX-resistance of NSCLC and SCLC [51,52,56].

The role of RLIP76 in PKC α -mediated resistance signaling was analyzed by determination of IC₅₀ for DOX in RLIP76^{+/+} and RLIP76^{-/-} MEFs in the presence and absence of PKC α . RLIP76^{-/-} MEFs were significantly sensitive to DOX as compared to RLIP76^{+/+} MEFs. Depletion of PKC α did not affect the DOX-sensitivity of RLIP76^{-/-} MEFs. On the other hand PKC α depletion sensitized RLIP76^{+/+} MEFs by 2.2 fold. These results demonstrate that the effect of PKC α in mediated drugresistance requires the presence of functional RLIP76; that is, the primary function of PKC α with respect to DOX-resistance in NSCLC is to keep RLIP76 in its active phosphorylated state. The complete reversion of the resistance phenotype from NSCLC to that of SCLC upon depletion of PKC α and the complete inability of PKC α to affect resistance in RLIP76^{-/-} MEFs strongly support this conclusion.

7. Identification of membrane anchoring domains of RLIP76 and cellular localization

The cellular distribution of RLIP76 is of utmost importance due to its multi-functional nature as an ATP-dependent transporter, effector in Ras-Ral signal pathways, mitosis and receptormediated endocytosis [2,9,20,30,42,45]. Though our previous studies indicate RLIP76 to be associated with the membrane, particularly N-terminal domain, other investigators suggest a cytosolic distribution attached to cytoskeleton [38,46]. In the absence of

transmembrane helices in the primary structure of RLIP76, we selected several regions with high sequence homology to vector-peptides that are known to be capable of transmembrane transport of allocrites as candidate regions for membrane anchorage [30]. A series of deletion mutants of RLIP76 were constructed and effects of mutations on expression of the protein between cytosol and membrane as well as on transport properties were studied. The results of the study indicate aa 154-219 as important in membrane anchorage and that membrane anchorage is required for its transport function [3]. Immuno-histochemical co-localization of RLIP76 with Herceptin in H358 lung cancer cells transfected with deletion mutant of aa 171-185, in which the wild-type protein has been suppressed by siRNA, indicate aa 171-185 comprises a cell-surface epitope [3].

Multiple roles of RLIP76 such as ATP-dependent transporter, role as an effector protein in signaling pathways, mitosis, membrane ruffling and receptor-mediated endocytosis all indicate RLIP76 to be associated with the membrane (Fig. 1A). Primarily it is expressed in the plasma membrane or nuclear membrane and also in cytoplasm, allied with the cytoskeleton. Previous studies have shown that N-terminal domain of RLIP76 (N-RLIP76¹⁻³⁶⁷) can be extracted only in the presence of a detergent indicating it to be associated with the membrane whereas C-terminal domain of RLIP76 (C-RLIP76⁴¹⁰⁻⁶⁵⁵) is found in both aqueous and the detergent fractions [2,46]. The rat and mouse homologues of RLIP76, known as Ralbp1 [10] and RIP1 [13], respectively, appear to be associated with the membrane by our studies as well as studies by other investigators [10,13,58,59]. Immuno-histochemistry studies using antibodies against different regions of RLIP76 in human lung cancer cells lines indicate the existence of cell-surface epitope [3,48]. Human lung cancer cells incubated with anti-RLIP76 antibodies were checked for the sensitivity to DOX. Considerable decrease in IC₅₀ values towards DOX upon exposure to antibodies suggests the existence of cell-surface epitope [48].

In search for the potential GS-E binding site of RLIP76 by sequence homology with well-known GS-E binding proteins using the IBM Bioinformatics Group Multiple Sequence Alignment algorithm, several amino acids have been found to be the potential candidates. Both drug sensitivity and uptake studies indicated that substitution of S234, K237 and K244 with alanine markedly affects the transport function of RLIP76 and the binding of the GS-E with the mutants of RLIP76 as compared to the wild type protein (Fig. 1B).

8. RLIP76 as a novel link in stress defense and signaling pathways

RLIP76 is bound to clathrin, the AP2 adaptor protein and is shown to play a vital role in endocytosis [30,35,42-45]. However, its functional role in endocytosis had not been studied in RLIP76-deficient cells or tissues. Herein, we report that RLIP76 loss causes an almost complete cessation of clathrin-dependent endocytosis of EGFR, which is restored fully by wild-type RLIP76. Remarkably, mutant RLIP76 proteins selected for decreased affinity for glutathioneconjugates displayed proportionately the same loss in endocytosis capacity as in other functional measures including substrate-stimulated transport activity, or the ability to confer drug-accumulation defect and drug-resistance phenotype. The rate of clathrin-dependent endocytosis was found to be directly proportional to the ATPase and transport activity of RLIP76. These studies demonstrate that GS-E transport activity of RLIP76 is necessary for clathrin-dependent endocytosis. These fundamental observations give an insight about the functioning of the endocytosis apparatus, and its regulation by the mercapturic-acid pathway.

9. Heat-shock responses

Heat-shock (stress) proteins [Hsp] are a family of proteins that vary in size (10-110 kDa) and perform two essential functions within the cell. At homeostasis Hsp can behave as 'chaperones' assisting proper folding of and proper compartmentalization of other proteins. Hsp can unfold

and refold improperly folded proteins into the proper orientation or assist in targeting them for degradation. In a stress-induced environment (temperature, xenobiotics, radiation and oxidative injury) where a higher likelihood of denatured proteins can exist, Hsp can mediate by either re-naturing the protein, degrading the protein, protecting the protein from becoming denatured, or transporting it to a compartment where it can be degraded. All of these actions assist the cell in maintaining its integrity [60]. It is known that many Hsp are regulated by Heat-Shock Factor 1 (Hsf-1). Hsf-1 is a transcription factor that forms a ternary-complex with some of the Hsp (inactive form). Upon stress, the Hsp is released and Hsf-1 is allowed to bind to DNA, which up-regulates and increases the Hsp production assisting in relief from the impending stress. It was recently discovered that Hsf-1 forms a complex with RLIP76 [38, 41]. Upon stress, the *ras* signaling pathway is activated and RLIP76 is removed from the complex, which allows Hsf-1 to translocate into the nucleus where it up-regulated the production of stress proteins. Thus, RLIP76 binding to Hsf-1 serves to inhibit Hsf-1 from increasing heat-shock protein RNA transcription. Our results are consistent with this postulate since loss of RLIP76 caused a stepwise up-regulation of heat-shock proteins [41,45].

Results of recent studies by Mivechi [36] have shown that RLIP76 is a primary regulator to Hsf-1, the transcription factor considered the master controller of the heat-shock response. Numerous heat-shock proteins and other chaperones are transcriptionally up-regulated by Hsf-1 in response to chemical oxidant-stressors as well as radiant-stressors that have in common augmentation of cellular lipidperoxidation levels. In RLIP76^{-/-} mice, heat-shock protein (Hsp1 α , Hsp40, Hsp105, mammalian stress protein 1, stress-induced phosphor-protein 1 and insulin-like growth factor binding protein 5) levels have been shown by us to be increased 2-5 fold by real-time Q-PCR [45]. We do not know whether this pathway of modulating heat-shock protein by RLIP76 by depletion or inhibition is operational in any particular cancer cells. If so, it is possible that cells with increased Hsf-1 levels should have a relatively lower RLIP76 transport activity due to inhibition, thus the effects of RLIP76 depletion could be exacerbated. In RLIP76^{-/-} MEFs, transfection with wild-type RLIP76 should function to suppress Hsf-1 activity to the base line level seen in RLIP76^{+/+} MEFs whereas Hsf-1-binding-deficient mutants of RLIP76 should not be able to suppress Hsf-1 [41].

10. Effect of RLIP76 disruption on GS-E and DOX-transport

We generated RLIP76^{+/+} and RLIP76^{-/-} mice colonies, based on genotyping [6,50]. Western-blot analysis of mouse tissues using anti-RLIP76 IgG confirmed detectable level of RLIP76 in RLIP76^{+/+} mouse tissues and its absence in RLIP76^{-/-} mice tissues [6]. Replacement of RLIP76 in RLIP76^{-/-} mouse tissues was examined in animals given 400 μ g/0.2 ml purified RLIP76 liposomes, i.p. Whereas Western-blot and immuno-histochemistry showed no immuno-logically detectable RLIP76 in RLIP76^{-/-} animals given control-liposomes, RLIP76 was clearly detected in mouse tissues at 24 h after a RLIP76-liposomes dose [6]. Consistent with the observed function of RLIP76 as a transporter of GS-E and DOX in cell culture studies [47], GS-E and DOX-transport in membrane vesicles was found to be decreased in RLIP76^{-/-} mice tissues. A greater than 80% loss of GS-E and DOX-transport activity was seen in the RLIP76^{-/-} mouse tissues. Delivery of RLIP76 to RLIP76^{-/-} animals via a liposomal delivery system completely reversed transport mechanisms [6].

11. RLIP76 loss results in accumulation of 4HNE and GS-HNE in mouse tissue

In RLIP76^{-/-} mice, the transport of DNP-SG, a model substrate used for GS-E transport studies, is impaired as indicated by loss of ~80% transport activity for DNP-SG in the IOVs prepared from the plasma membrane fraction of tissues [6,30]. Lipid-peroxidation products including lipid-hydroper-oxides and aldehydes were also increased in the tissues of these mice implying that GS-E formed physiologically from lipid-hydroperoxides would also accumulate in tissues

of RLIP76^{-/-} mice. Recently, we have addressed this question by directly measuring tissue levels of 4HNE and its GSH-conjugate (GS-HNE) using LCMS. Homogenates were prepared from freshly excised liver tissue from RLIP76^{+/+} and RLIP76^{-/-} mice and subjected to extraction for either 4HNE or the GS-HNE using the protocols described by us [50]. The results of these studies showed that both, 4HNE as well as GS-HNE were increased by about three-fold in the RLIP76^{-/-} mouse liver tissue. These studies demonstrated for the first time that loss of RLIP76 results in the accumulation of endogenously generated electrophiles and their GSH-conjugates *in vivo* [50]. The significance of RLIP76-mediated transport of GS-HNE necessitates a robust and facile analytical method to determine intracellular GS-HNE and HNE levels.

12. POB1

Yeast two-hybrid screening with RLIP76 as bait has yielded POB1 (Partner of RLIP76/RalBP1), also an endocytosis protein [61]. Both proteins are found in signal transduction complexes for membrane tyrosine-kinase receptors (such as insulin and EGF-R) and are phosphorylated [25]. Interestingly, POB1 has also been shown to be a pro-apoptotic protein when expressed in prostate cancer cells [39], which have very high RLIP76 content [7]. Reasoning that this may be due to an inhibitory effect of POB1 on the transport activity of RLIP76, we tested the effects of POB1 on the transport activity and drug-resistance mediating effects of RLIP76. POB1 bound specifically to RLIP76 through the C-terminal domain of RLIP76 and inhibited transport activity as well as RLIP76 mediated drug-resistance [40].

The human POB1 also referred to as REPS2, protein is highly conserved in mammals where it has been suggested to function as a molecular scaffold recruiting proteins involved in vesicular traffic and linking them to the actin cytoskeleton remodeling machinery [62]. POB1 was identified as a 657 amino acid protein, contains the C-terminal coiled-coil protein-protein interaction domain that is involved in RLIP76 binding and was found highly expressed in androgen-dependent prostate cancer cell lines [25,39], is down regulated during prostate cancer progression [63]. It has been shown that over-expression of POB1 and its binding with RLIP76 induce apoptosis in prostate cancer cells [39].

13. Conclusions

Studies summarized in this review provide strong evidence for the role of RLIP76 as an effector protein which catalyzes the efflux of GS-E, a process which is a crucial component of diverse cellular signaling pathways including mitosis, proliferation, differentiation, apoptosis, and endocytosis. The linkage of RLIP76 to the Ral and Ras pathways and in particular to the Rho/Rac pathway, which is known to control stress-responses, is also of fundamental significance and similar links have not been found for other transporters. Although clear evidence has been provided for the interaction of RLIP76 with these pathways, mechanistic explanations regarding how RLIP76 is involved in mediating a diverse array of functions has previously been far from clear. Through its protein-protein binding motifs, it has clearly been shown to bind important signaling proteins including Ral, AP2 clathrin-adaptor protein [30,53], POB1 [39,40,62,63], CDK1 [42], and Hsp90 as well as Hsf1 [38,41], the directionality of signaling has been far from clear, and have left open questions as to whether these proteins are regulating some effector function of RLIP76, or whether RLIP76 is functioning as a regulator of these signaling proteins. In this regard, it should be noted that when originally cloned, RLIP76, was predicted to be an effector protein [10,13,14]. Our previous and present studies have clearly demonstrated an effector function for RLIP76, as an active nucleotidase which is capable of coupling ATPase-activity with trans-membrane movement of several allocrites [23,30,33, 46-48,64,65]. Previous studies indicating that RLIP76 also functions in mitotic spindle apparatus movement [9,30], in membrane movement during endocytosis and exocytosis [30, 42-45], taken together with observations by us and by others that the C-terminal domain of

RLIP76 is found both in membrane as well as cytosol, that it contains an active ATPase domain, strongly support the proposal by us as well as others that RLIP76 is a modular protein containing multiple domains which may perform distinct functions at distinct intracellular sites [20,21,30-32]. Thus, the findings that RLIP76 functions in the mitotic spindle, endocytosis, exocytosis, and transport are not mutually exclusive or contradictory, and indicate different domains of RLIP76, which function in ATPase, protein-protein binding, GAP-activity, and membrane insertion, may be serving distinct functions in different cellular compartments. Recently, RLIP76 has also been proposed to be involved in the mechanism of pharmacoresistance [66] and RLIP76 antibodies increased intracellular levels of 4HNE, decreased levels of GSH and activate C-Jun NH₂ kinase signaling (JNK), thus inducing oxidative stress-mediated cell apoptosis [67]. In lung cancer cells, RLIP76 was shown to be a major transporter of DOX and also GS-E, representing about two-thirds of the transport-capacity. Pgp and multi-drug-resistance protein (MRP) were responsible for the remaining transport activity [47,68].

14. Significance

RLIP76 is a fundamental link between biochemical pathways of GSH-linked metabolism of xenobiotics and stress-defense signaling pathways. It represents a stress-resistance effector that plays a pivotal role in defending normal cells from poisons, and cancer cells from apoptosis. Thus augmentation of RLIP76 in normal cells that are stressed or injured may be a pharmacological method for treatment of poisoning and wounds, and controlled depletion or inhibition of RLIP76 should naturally target malignant cell that rely on the mercapturic-acid pathway to protect themselves from apoptosis. The rate regulatory role of RLIP76 in endocytosis has many unexplored implications with respect to this mechanism that functions to terminate signaling initiated by ligand-receptor binding. RLIP76 plays a central role in radiation and chemotherapy-resistance through its activity as a multi-specific ATP-dependent transporter.

Acknowledgements

This work was supported in part by National Institutes of Health Grants CA 77495 and CA 104661, Cancer Research Foundation of North Texas, Institute for Cancer Research and the Joe & Jessie Crump Fund for Medical Education.

Abbreviations

RLIP76 (RalBP1), Ral-interacting protein
 GSH, glutathione
 GS-E, glutathione-electrophile-conjugates
 DNP-SG, dinitrophenyl S-glutathione
 DOX, doxorubicin
 4HNE, 4-hydroxy-t-nonenal
 IOVs, in-side-out vesicles
 MDR, multi-drug-resistance
 Pgp, P-glycoprotein
 MRP1, multi-drug-resistance associated protein
 SCLC, small cell lung cancer
 NSCLC, non-small cell lung cancer
 POB1, partner of RalBP1
 AP-2, adaptor protein

REFERENCES

- [1]. Awasthi S, Singhal SS, Srivastava SK, Zimniak P, Bajpai KK, Saxena M, et al. Adenosine-triphosphate-dependent transport of doxorubicin, daunomyicin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. *J Clin Invest* 1994;93:958–65. [PubMed: 7907606]
- [2]. Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, Pikula S, et al. Novel function of human RLIP76: ATP-dependent transport of glutathione-conjugates and doxorubicin. *Biochemistry* 2000;39:9327–34. [PubMed: 10924126]
- [3]. Yadav S, Singhal SS, Singhal J, Wickramarachchi D, Kuntson E, Albrecht TB, et al. Identification of membrane-anchoring domains of RLIP76 using deletion mutants analyses. *Biochemistry* 2004;43:16243–5. [PubMed: 15610018]
- [4]. Sharma R, Singhal SS, Wickramarachchi D, Awasthi YC, Awasthi S. RLIP76-mediated transport of leukotriene C₄ in cancer cells: implications in drug-resistance. *Int J Cancer* 2004;112:934–42. [PubMed: 15386349]
- [5]. Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, Awasthi S. RLIP76 transports vinorelbine and mediates drug-resistance in non-small cell lung cancer. *Cancer Res* 2005;65:991–8. [PubMed: 15705900]
- [6]. Awasthi S, Singhal SS, Yadav S, Singhal J, Drake K, Nadkar A, et al. RLIP76 is a major determinant of radiation-sensitivity. *Cancer Res* 2005;65:6022–8. [PubMed: 16024601]
- [7]. Singhal SS, Awasthi YC, Awasthi S. Regression of melanoma in a murine model by RLIP76-depletion. *Cancer Res* 2006;66:2354–60. [PubMed: 16489041]
- [8]. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor P, Awasthi YC, et al. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76. *Cancer Res* 2007;67:4382–9. [PubMed: 17483352]
- [9]. Quaroni A, Paul EC. Cytoctrin is a Ral-binding protein involved in the assembly and function of the mitotic-apparatus. *J Cell Sci* 1999;112:707–18. [PubMed: 9973605]
- [10]. Cantor SB, Urano T, Feig LA. Identification and characterization of Ral-binding-protein1, a potential downstream target of Ral GTPases. *Mol Cell Biol* 1995;15:4578–84. [PubMed: 7623849]
- [11]. Diekmann D, Brill S, Garrett MD, Totty N, Hsuan J, Monfries C, et al. Bcr encodes a GTPase-activating protein for p21rac. *Nature* 1991;351:400–2. [PubMed: 1903516]
- [12]. Hinoi T, Kishida S, Koyama S, Ikeda M, Matsuura Y, Kikuchi A. Post-translational modifications of Ras and Ral are important for the action of Ral GDP dissociation stimulator. *J Biol Chem* 1996;271:19710–6. [PubMed: 8702675]
- [13]. Park SH, Weinberg RA. A putative effector of Ral has homology to Rho/Rac GTPase-activating proteins. *Oncogene* 1995;11:2349–55. [PubMed: 8570186]
- [14]. Jullien-Flores V, Dorseuil O, Romero F, Letourneur F, Saragosti S, Berger R, et al. Bridging Ral-GTPase to Rho-pathways. RLIP76, a Ral-effector with CDC42/Rac GTPase-activating protein activity. *J Biol Chem* 1995;270:22473–7. [PubMed: 7673236]
- [15]. Sharma R, Awasthi YC, Yang Y, Sharma A, Singhal SS, Awasthi S. Energy-dependent transport of xenobiotics and its relevance to multidrug-resistance. *Curr Cancer Drug Targets* 2003;3:89–107. [PubMed: 12678713]
- [16]. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide-polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux-transporters. *Int J Toxicol* 2006;25:231–59. [PubMed: 16815813]
- [17]. Higgins CF. Multiple molecular mechanisms for multidrug-resistance transporters. *Nature* 2007;446:749–57. [PubMed: 17429392]
- [18]. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. *Cancer Metastasis Rev* 2007;26:183–201. [PubMed: 17323126]
- [19]. Sharom FJ. ABC multidrug-transporters: structure, function and role in chemoresistance. *Pharmacogenomics* 2008;9:105–27. [PubMed: 18154452]
- [20]. Jullien-Flores V, Mahe Y, Mirey G, Leprince C, Meunier-Bisceuil B, Sorkin A, et al. RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor-endocytosis. *J Cell Sci* 2003;113:2837–44. [PubMed: 10910768]

- [21]. Mirey G, Balakireva M, L'Hoste S, Rossé C, Voegelings S, Camonis J. A Ral guanine exchange factor-Ral pathway is conserved in *Drosophila melanogaster* and sheds new light on the connectivity of the Ral, Ras, and Rap-pathways. *Mol Cell Biol* 2003;23:1112–24. [PubMed: 12529414]
- [22]. www.ensembl.org human exon report
- [23]. Singhal SS, Singhal J, Sharma R, Singh SV, Zimniak P, Awasthi YC, et al. Role of RLIP76 in lung cancer doxorubicin-resistance: I The ATPase activity of RLIP76 correlates with doxorubicin and 4HNE-resistance in lung cancer cells. *Int J Oncol* 2003;22:365–75. [PubMed: 12527936]
- [24]. Bauer B, Mirey G, Vetter IR, Garcia-Ranea JA, Valencia A, Wittinghofer A, et al. Effector recognition by the small GTP-binding proteins Ras and Ral. *J Biol Chem* 1999;274:17763–70. [PubMed: 10364219]
- [25]. Ikeda M, Ishida O, Hinoi T, Kishida S, Kikuchi AJ. Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral. *J Biol Chem* 1998;273:814–21. [PubMed: 9422736]
- [26]. Awasthi S, Singhal SS, Srivastava SK, Torman RT, Zimniak P, Pikula J, et al. ATP dependent human erythrocyte glutathione-conjugate-transporter. I. Purification, photoaffinity-labeling, and kinetic characteristics of ATPase-activity. *Biochemistry* 1998;37:5231–8. [PubMed: 9548754]
- [27]. Awasthi S, Singhal SS, Pikula S, Piper JT, Srivastava SK, Torman RT, et al. ATP-dependent human erythrocyte glutathione-conjugate-transporter. II. Functional reconstitution of transport-activity. *Biochemistry* 1998;37:5239–48. [PubMed: 9548755]
- [28]. Awasthi S, Singhal SS, Pandya U, Gopal S, Zimniak P, Singh SV, et al. ATP-dependent colchicines transport by human erythrocyte glutathione-conjugate-transporter. *Toxicol Appl Pharmacol* 1999;155:215–26. [PubMed: 10079207]
- [29]. Oshiro T, Koyama S, Sugiyama S, Kondo A, Onodera Y, Asahara T, et al. Interaction of POB1, a downstream molecule of small G protein Ral, with PAG2, a paxillin-binding protein, is involved in cell migration. *J Biol Chem* 2002;277:38618–26. [PubMed: 12149250]
- [30]. Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi YC. Transport of glutathione-conjugates and chemotherapeutic drugs by RLIP76: a novel link between G-protein and tyrosine-kinase signaling and drug-resistance. *Int J Cancer* 2003;106:635–46. [PubMed: 12866021]
- [31]. Awasthi S, Sharma R, Singhal SS, Zimniak P, Awasthi YC. RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics. *Drug Metab Dispos* 2002;30:1300–10. [PubMed: 12433796]
- [32]. Awasthi YC, Sharma R, Yadav S, Dwivedi S, Sharma A, Awasthi S. The non-ABC drug-transporter RLIP76 plays a major role in the mechanisms of drug-resistance. *Curr Drug Metab* 2007;8:315–23. [PubMed: 17504221]
- [33]. Yadav S, Zajac E, Singhal SS, Awasthi S. Linking stress-signaling, glutathione-metabolism, signaling pathways and xenobiotic-transporters. *Cancer Metastasis Rev* 2007;26:59–69. [PubMed: 17260165]
- [34]. Goldfinger LE, Ptak C, Jeffery ED, Shabanowitz J, Hunt DF, Ginsberg MH. RLIP76 (RalBP1) is an R-Ras effector that mediates adhesion-dependent Rac-activation and cell migration. *J Cell Biol* 2006;174:877–88. [PubMed: 16966426]
- [35]. Morinaka K, Koyama S, Nakashima S, Hinoi T, Okawa K, Iwamatsu A, et al. Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis. *Oncogene* 1999;18:5915–22. [PubMed: 10557078]
- [36]. Cheng J, Sharma R, Yang Y, Singhal SS, Sharma A, Saini MK, et al. Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative-stress. *J Biol Chem* 2001;276:41213–2. [PubMed: 11522795]
- [37]. Yang Y, Sharma A, Sharma R, Patrick B, Singhal SS, Zimniak P, et al. Cells preconditioned with mild, transient UVA-irradiation acquire resistance to oxidative-stress and UVA-induced apoptosis: role of 4-HNE in UVA-mediated signaling for apoptosis. *J Biol Chem* 2003;278:41380–8. [PubMed: 12888579]
- [38]. Hu Y, Mivechi NF. HSF-1 interacts with Ral-binding-protein 1 in a stress-responsive, multi-protein complex with HSP90 *in vivo*. *J Biol Chem* 2003;278:17299–306. [PubMed: 12621024]
- [39]. Oosterhoff JK, Penninkhof F, Brinkmann AO, Grootegeed JA, Blok LG. POB1 is down-regulated during human prostate cancer progression and inhibits growth factor signaling in prostate cancer cells. *Oncogene* 2003;22:2920–5. [PubMed: 12771942]

- [40]. Yadav S, Zajac E, Singhal SS, Singhal J, Drake K, Awasthi YC, et al. POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis. *Biochem Biophys Res Commun* 2005;328:1003–9. [PubMed: 15707977]
- [41]. Singhal SS, Yadav S, Drake K, Singhal J, Awasthi S. Hsf-1 and POB1 induce drug-sensitivity and apoptosis by inhibiting Ralbp1. *J Biol Chem* 2008;283:19714–29. [PubMed: 18474607]
- [42]. Rosse C, L'Hoste S, Offner N, Picard A, Camonis JH. RLIP, an effector of the Ral-GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis. *J Biol Chem* 2003;278:30597–604. [PubMed: 12775724]
- [43]. Matsuzaki T, Hanai S, Kishi H, Liu Z, Bao Y, Kikuchi A, et al. Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ral-binding protein 1-dependent pathway. *J Biol Chem* 2002;277:19008–1. [PubMed: 11882656]
- [44]. Moskalenko S, Henry DO, Rosse C, Mirey G, Camonis JH, White MA. The exocyst is a Ral-effector complex. *Nat Cell Biol* 2002;4:66–72. [PubMed: 11740492]
- [45]. Singhal, SS.; Awasthi, S. Toxicology of glutathione S-transferases. CRC Press; Boca Raton, FL: 2006. Glutathione-conjugate transport and stress-response signaling: role of RLIP76; p. 231–56.
- [46]. Awasthi S, Cheng J, Singhal SS, Sharma R, Pandya U, Singh SV, et al. Functional reassembly of xenobiotic-transport from the N-terminal and C-terminal domains of RLIP76 and identification of ATP-binding sequences. *Biochemistry* 2001;40:4159–68. [PubMed: 11300797]
- [47]. Awasthi S, Singhal SS, Singhal J, Cheng J, Zimniak P, Awasthi YC. Role of RLIP76 in lung cancer doxorubicinresistance: II. Doxorubicin-transport in lung cancer by RLIP76. *Int J Oncol* 2003;22:713–20. [PubMed: 12632060]
- [48]. Awasthi S, Singhal SS, Singhal J, Yang Y, Zimniak P, Awasthi YC. Role of RLIP76 in lung cancer doxorubicinresistance: III. Anti-RLIP76-antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicincytotoxicity. *Int J Oncol* 2003;22:721–32. [PubMed: 12632061]
- [49]. Sauer B. Inducible gene targeting in mice using the Cre/lox system. *Methods* 1998;14:381–92. [PubMed: 9608509]
- [50]. Singhal J, Singhal SS, Yadav S, Warnke M, Yacoub A, Dent P, et al. RLIP76 in defense of radiation and chemicalpoisoning. *Int J Rad Oncol Biol Phys* 2008;72:553–61.
- [51]. Singhal SS, Yadav S, Singhal J, Drake K, Awasthi YC, Awasthi S. The role of PKC α and RLIP76 in transportmediated doxorubicin-resistance in lung cancer. *FEBS Lett* 2005;579:4635–41. [PubMed: 16087181]
- [52]. Singhal SS, Wickramarachchi D, Singhal J, Yadav S, Awasthi YC, Awasthi S. Determinants of differential doxorubicin-sensitivity between SCLC and NSCLC. *FEBS Lett* 2006;580:2258–64. [PubMed: 16579994]
- [53]. Kariya K, Koyama S, Nakashima S, Oshiro T, Morinaka K, Kikuchi A. Regulation of complex formation of POB1/epsin/adaptor protein complex 2 by mitotic phosphorylation. *J Biol Chem* 2000;275:18399–406. [PubMed: 10764745]
- [54]. Nakashima S, Morinaka K, Koyama S, Ikeda M, Kishida M, Okawa K, et al. Small G protein Ral and its downstream molecules regulate endocytosis of EGF and insulinreceptors. *EMBO J* 1999;18:3629–42. [PubMed: 10393179]
- [55]. Carter LL, Redelmeier TE, Woollenweber LA, Schmid SL. Multiple GTP-binding proteins participate in clathrincoated vesicle-mediated endocytosis. *J Cell Biol* 1993;120:37–45. [PubMed: 8416994]
- [56]. Singhal SS, Yadav S, Singhal J, Awasthi YC, Awasthi S. Mitogenic and drug-resistance mediating effects of PKC α require RLIP76. *Biochem Biophys Res Commun* 2006;348:722–7. [PubMed: 16890208]
- [57]. Herlevsen MC, Theodorescu D. Mass spectroscopic phosphoprotein mapping of Ral-binding-protein1 (RalBP1/Rip1/RLIP76). *Biochem Biophys Res Commun* 2007;362:56–62. [PubMed: 17706599]
- [58]. Pikula S, Hayden JB, Awasthi S, Awasthi YC, Zimniak P. Organic anion-transporting ATPase of rat liver. I. Purification, photoaffinity labeling, and regulation by phosphorylation. *J Biol Chem* 1994;269:27566–73. [PubMed: 7961673]

- [59]. Pikula S, Hayden JB, Awasthi S, Awasthi YC, Zimniak P. Organic anion-transporting ATPase of rat liver. II. Functional reconstitution of active-transport and regulation by phosphorylation. *J Biol Chem* 1994;269:27574–9. [PubMed: 7961674]
- [60]. Bernat BA, Laughlin LT, Armstrong RN. Fosfomycinresistance protein (FosA) is a manganese metalloglutathione-transferase related to glyoxalase I and the extradiol dioxygenases. *Biochemistry* 1997;36:3050–5. [PubMed: 9115979]
- [61]. Xu J, Zhou Z, Zeng L, Huang Y, Zhao W, Cheng C, et al. Cloning, expression and characterization of a novel human REPS1 gene. *Biochim Biophys Acta* 2001;1522:118–21. [PubMed: 11750063]
- [62]. Koshiba S, Kigawa T, Iwahara J, Kikuchi A, Yokoyama S. Solution structure of the Eps15 homology domain of a human POB1 (partner of RalBP1). *FEBS Lett* 1999;442:138–42. [PubMed: 9928989]
- [63]. Tomassi L, Costantini A, Corallino S, Santonico E, Carducci M, Cesareni G, et al. The central proline-rich region of POB1/REPS2 plays a regulatory role in epidermal-growthfactor-receptor endocytosis by binding to 14-3-3 and SH3 domain-containing proteins. *BMC Biochem* 2008;9:21. [PubMed: 18647389]
- [64]. Singhal SS, Yadav S, Singhal J, Zajac E, Awasthi YC, Awasthi S. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. *Biochem Pharmacol* 2005;70:481–8. [PubMed: 15950949]
- [65]. Sharma R, Singhal SS, Cheng J, Yang Y, Sharma A, Zimniak P, et al. RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes. *Arch Biochem Biophys* 2001;391:171–9. [PubMed: 11437348]
- [66]. Leschziner GD, Jorgensen AL, Andrew T, Williamson PR, Marson AG, Coffey AJ, et al. The association between polymorphisms in RLIP76 and drug-response in epilepsy. *Pharmacogenomics* 2007;8:1715–22. [PubMed: 18086001]
- [67]. Margutti P, Matarrese P, Conti F, Colasanti T, Delunardo F, Capozzi A, et al. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative-stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis. *Blood* 2008;111:4559–70. [PubMed: 17993611]
- [68]. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science* 1992;258:1650–4. [PubMed: 1360704]

Fig. 1. Membrane localization of RLIP76. Immuno-histochemistry studies using antibodies against RLIP76 on live-unfixed H226 cells indicated a membrane associated pattern. NSCLC H226 cells grown on sterilized cover-slips were incubated with anti-RLIP76-IgG as the primary-antibodies followed by FITC-conjugated goat-anti-rabbit-IgG as the secondary-antibodies. DAPI was used as a nuclear counter-stain. The cells were analyzed by Zeiss LSM 510 META laser-scanning fluorescence microscopy (panel A). Interactions of RLIP76 with glutathione-conjugates (panel B).